Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P50502 (
Hip
)
7,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
hsp70-interacting protein
Hip
participates in the assembly pathway for progesterone receptor complexes. During assembly,
Hip
appears at early assembly stages in a transient manner that parallels hsp70 interactions. In this study, a cDNA for human
Hip
was used to develop various mutant
Hip
forms in the initial mapping of functions to particular
Hip
structural elements.
Hip
regions targeted for deletion and/or truncation included the C-terminal region (which has some limited homology with Saccharomyces cerevisiae Sti1 and its vertebrate homolog p60), a glycine-glycine-methionine-proline (GGMP) tandem repeat, and a tetratricopeptide repeat (TPR). Binding of
Hip
to hsp70's ATPase domain was lost with deletions from the TPR and from an adjoining highly charged region; correspondingly, these
Hip
mutant forms were not recovered in receptor complexes. Truncation of
Hip
's Sti1-related C terminus resulted in
Hip
binding to hsp70 in a manner suggestive of a misfolded peptide substrate; this hsp70 binding was localized to the GGMP tandem repeat. Mutants lacking either the C terminus or the GGMP tandem repeat were still recovered in receptor complexes. Truncations from
Hip
's N terminus resulted in an apparent loss of
Hip
homo-oligomerization, but these mutants retained association with hsp70 and were recovered in receptor complexes. This mutational analysis indicates that
Hip
's TPR is required for binding of
Hip
with hsp70's ATPase domain. In addition, some data suggest that hsp70's peptide-binding domain may alternately or concomitantly bind to
Hip
's GGMP repeat in a manner regulated by Sti1-related sequences.
...
PMID:Mutational analysis of the hsp70-interacting protein Hip. 888 50